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Abstract The biological subtype of breast cancer influ-
ences the selection of systemic therapy. Distinction
between luminal A and B cancers depends on consistent
assessment of Ki-67, but substantial intra-observer and
inter-observer variability exists when immunohistochem-
istry (IHC) is used. We compared RT-qPCR with IHC in
the assessment of Ki-67 and other standard factors used in
breast cancer subtyping. RNA was extracted from archival
breast tumour tissue of 769 women randomly assigned to
the FinHer trial. Cancer ESR1, PGR, ERBB2 and MKI67
mRNA content was quantitated with an RT-qPCR assay.
Local pathologists assessed ER, PgR and Ki-67 expression
using IHC. HER2 amplification was identified with
chromogenic in situ hybridization (CISH) centrally. The
results were correlated with distant disease-free survival
(DDFS) and overall survival (OS). qPCR-based and IHC-
based assessments of ER and PgR showed good concor-
dance. Both low tumour MKI67 mRNA (RT-qPCR) and
Ki-67 protein (IHC) levels were prognostic for favourable
DDFS [hazard ratio (HR) 0.42, 95 % CI 0.25–0.71,
P = 0.001; and HR 0.56, 0.37–0.84, P = 0.005, respec-
tively] and OS. In multivariable analyses, cancer MKI67
mRNA content had independent influence on DDFS (ad-
justed HR 0.51, 95 % CI 0.29–0.89, P = 0.019) while Ki-
67 protein expression had not any influence (P = 0.266)
whereas both assessments influenced independently OS.
Luminal B patients treated with docetaxel-FEC had more
favourable DDFS and OS than those treated with vinorel-
bine-FEC when the subtype was defined by RT-qPCR (for
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DDFS, HR 0.52, 95 % CI 0.29–0.94, P = 0.031), but not
when defined using IHC. Breast cancer subtypes approxi-
mated with RT-qPCR and IHC show good concordance,
but cancer MKI67 mRNA content correlated slightly better
with DDFS than Ki-67 expression. The findings based on
MKI67 mRNA content suggest that patients with luminal B
cancer benefit more from docetaxel-FEC than from
vinorelbine-FEC.
Keywords Breast cancer  Molecular subtypes  Ki-67 
Prediction  Immunohistochemistry  RT-qPCR
Abbreviations
ESR1/ER Oestrogen Receptor alpha
CISH Chromogenic in situ hybridization
Cq Quantification cycle
DDFS Distant disease-free survival
FEC Fluorouracil & epirubicin,
cyclophosphamide chemotherapy
FFPE Formalin fixed paraffin embedded
GOI Gene of interest
HR Hazard ratio
IHC Immunohistochemistry
mRNA Messenger ribonucleic acid
MKI67/
Ki-67
Marker of proliferation Ki-67
OS Overall survival
PGR/PgR Progesterone receptor
REF Reference gene
RT-qPCR Reverse transcription quantitative real-time
polymerase chain reaction
ERBB2/
HER2
Human epidermal growth factor receptor 2
Introduction
Biological subtyping of breast cancer is an integral part of
the standard evaluation of patients diagnosed with breast
cancer. Subtyping can be done with gene expression arrays
[1], but the molecular subtypes are frequently approxi-
mated with immunohistochemistry (IHC) due to its wide
availability and low cost. However, assays for cancer
oestrogen receptor (ER), progesterone receptor (PgR) and
human epidermal growth factor receptor-2 (HER2)
expression by IHC have an up to 20 % risk for discordant
or erroneous results [2, 3], and making a distinction
between luminal A and luminal B breast cancer requires
assessment with the proliferation marker Ki-67, which is
prone to high intra- and inter-observer assessment vari-
ability [4, 5].
In this study, we compared assessment of breast cancer
key biomarkers, ER, PgR, HER2 and Ki-67 quantitatively
using RT-qPCR with their assessment using IHC or in situ
hybridization as a part of the clinical routine in breast
cancer subtyping and prediction of patient outcome. We
hypothesized that quantifying Ki-67 with RT-qPCR might
result in more robust outcome predictions. To our knowl-
edge, few such comparative data are available.
Methods
Patients
The clinical data and breast tumour tissue samples were col-
lected within the FinHer trial (identifier ISRCTN76560285),
where 1010 women with axillary node–positive or high-risk
axillary node-negative breast cancer were randomly assigned
between October 2000 and September 2003 to receive either
three cycles of docetaxel followed by three cycles of fluo-
rouracil, epirubicin and cyclophosphamide (FEC) or three
cycles of vinorelbine followed by three cycles of FEC [6, 7].
Breast tumour erbB2 (HER2) copy numbers were deter-
mined centrally by chromogenic in situ hybridization
(CISH), and women with HER2-positive cancer (n = 232)
had a second randomisation between nine weekly infusions
of trastuzumab, given concomitantly with either docetaxel
or vinorelbine, and similar chemotherapy without trastuzu-
mab. After a median follow–up time of 62 months since
randomisation, women assigned to docetaxel had better
distant disease-free survival (DDFS, the primary objective)
than those assigned to vinorelbine (HR 0.66, 95 % CI
0.49–0.91; P = 0.010) [6]. The absolute benefit in 5-year
DDFS in favour of the docetaxel plus FEC regimen was
5.2 % (86.8 vs 81.6 %), and 3.3 % (92.6 vs 89.3 %) for
overall survival (OS) across all biological subtypes [6].
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Immunohistochemistry
Immunostaining for ER, PgR, HER2 and Ki-67 was
performed on tissue sections cut from formalin-fixed,
paraffin-embedded (FFPE) tumour tissue at the local
pathology laboratories of the 17 study sites (all located in
Finland) according to each laboratory’s standard
procedures.
ER and PgR were considered positive when 10 % or
more of the cancer cells stained positively. Ki-67 assays
were analysed by estimating the proportion of positively
staining cancer cell nuclei out of all cancer cell nuclei in
the tissue section, and the result was provided as a per-
centage ranging from 0 to 100 %. For the present study,
Ki-67 expression was considered positive when C20 % of
cancer cell nuclei stained positively. Local pathologists
interpreted the ER, PgR and Ki-67 immunostaining results,
as per each institute’s standard practice.
Chromogenic in situ hybridization (CISH)
Tumours with a score of 2? or 3? (on a scale of 0 to 3?)
for HER2 expression in IHC were further analysed for
HER2 gene amplification by CISH in one of two central
laboratories. The HER2 status was considered positive
when six or more gene copies per nucleus were present. As
in the original trial [6, 7], in the present study, cancer
HER2 status was considered positive whenever CISH for
HER2 was positive, and negative whenever CISH was
negative, regardless of the degree of HER2 protein
expression in IHC.
RT-qPCR
After pathologic confirmation of representativeness of the
tissue sections for presence of cancer, a single whole-face
10-lm-thick slice from each FFPE tumour block was
processed with the RNXtract RNA extraction kit (BioN-
Tech Diagnostics GmbH, Mainz) using a magnetic parti-
cle-based assay (Supplemental file 1A). RT-qPCR was
done with the MammaTyper kit (BioNTech Diagnostics
GmbH, Mainz) for ESR1, PGR, ERBB2 and MKI67, and
the two reference genes B2 M and CALM2 on a Versant
kPCR system (Siemens, Erlangen, Germany) by applying
one cycle of primer-specific reverse transcription followed
by 40 cycles of nucleic acid amplification (Supplemental
file 1B). The median quantification cycle (Cq) for each of
the four genes of interest (GOI) were normalized against
the two reference genes (REF) and presented as DDCq
values relative to the positive control, obtained after sub-
tracting the DCq value of the positive control (pc) from the
DCq of the sample (s) by the formula
40  DDCq GOIð ÞS¼ 40  Cq GOI½ S- meanCq REF½ S
 
 Cq GOI½ pc- meanCq REF½ pc
 
:
To exclude a major influence of a varying tumour cell
content for the assay results, sensitivity studies were
undertaken similarly as previously reported [8]. A series of
extreme cases with low content of invasive carcinoma and
varying amount of DCIS were analysed before and after
macrodissection and it could be confirmed that the TCC did
not influence the final test result [9, Laible et al. submitted].
Therefore, a major influence of TCC on MKI67 mRNA
expression can be excluded. Cut-offs for the markers
ERBB2, ESR1 and PGR were defined in an independent
technical cohort based on reference pathology IHC results.
Prognostic and predictive value of MKI67 cut-offs had
previously been analysed by testing objective cut-offs in
562 Affymetrix U133 A datasets from breast cancer patient
cohorts having received either no systemic therapy, only
endocrine treatment or chemo-endocrine regimen [10]. In
view of these analyses, theMKI67 cut-off was set at the 3rd
quartile of the normally distributed MKI67 expression data
from 90 FFPE breast cancer reference tumour samples and
thus ought to reflect a correlate to the standard Ki-67 cut-
off at 20 % positively stained nuclei.
Definition of breast cancer biological subtypes
After defining each of the four biomarkers either positive or
negative, the molecular subtype of each tumour was deter-
mined using a slightly modified version of the currently
proposed IHC-based breast cancer molecular subtyping
algorithm [1] (Supplemental File 1C). In brief, luminal A
cancers were defined as having high ESR1 and/or PGR
mRNAcontent and lowERBB2 andMKI67 content. Luminal
B cancers were defined as having high cancer ESR1 and
MKI67 content, or high ESR1 content but low PGR and
ERBB2 content. Cancers with a high ERBB2mRNA content
were considered as HER2-positive cancers and were not
further categorized into luminal and non-luminal (‘‘en-
riched’’) lesions. Triple-negative cancers consisted of can-
cers that had low ESR1, PGR and ERBB2 mRNA content
irrespective of cancer MKI67 mRNA content.
The same scheme was used to categorize the cancers
according to the IHC and CISH results, but using protein
expression (at IHC) and the number of HER2 gene copies
(at CISH) in place of cancer mRNA content. For example,
cancers that were positive for ER and PgR (with C10 % of
the nuclei that were positive in each staining), HER2
negative (by CISH) and had low Ki-67 (\20 % of nuclei
stained positively at IHC) were considered luminal A
cancers.
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Statistical methods
The results were analysed according to a statistical analysis
plan written and approved prior to the initiation of the
study, and the RT-qPCR results were interpreted blinded to
the clinical information. Kappa (j) statistic numeric values
are categorized into poor (B0.2), fair ([0.2–0.4), moderate
([0.4–0.6), good ([0.6–0.8) and very good ([0.8) associ-
ations, and were used as a measure of positive percent
agreement (PPA), negative percent agreement (NPA) and
overall percent agreement (OPA). The tests are accompa-
nied by their respective 95 % confidence intervals (95 %
CI). A two-sided P value\0.05 was considered significant.
The primary clinical endpoint was DDFS, defined as the
time period between the date of randomisation and the date
of first distant metastasis or the date of death when death
preceded detection of distant recurrence. Overall survival
(OS) was defined as the time period between the date of
randomisation and the date of death. Survival was analysed
using the Kaplan–Meier method.
Univariable and multivariable Cox proportional hazards
models were constructed to compare prognosis between
groups and to study the interactions between variables.
Hazard ratios (HRs) were calculated using a univariable
Cox model. In multivariable Cox models, a backward
selection procedure was used to adjust for the covariables.
Results
Patients
An RT-qPCR assay of ESR1, PGR, ERBB2 andMKI67 was
successfully performed from breast cancer tissues of 769
(76 %) out of the 1010 patients entered to the FinHer trial.
In the remaining 241 cases, cancer tissues were not avail-
able, and the tissue block did not consist mostly of cancer
cells, or RNA extraction did not yield good-quality mRNA.
We included in this study all 719 (71 % out of 1010) cases
with successful RT-qPCR assay of the four genes and with
IHC data available for subtyping. The inaccessibility rate
to the tissue samples was similar across the study treatment
arms (a modified CONSORT diagram shown in Supple-
mental file 1D). The characteristics of the patients and
tumours included in the present study (Table 1) were
similar to those of the entire FinHer trial cohort [7].
The median age of the patients at study entry was 50.9
years (range, 25.5–65.8). Tumours had a mean diameter of
26 mm ± 16 mm (6–150 mm), and the majority (n = 637,
88.6 %) had given rise to regional lymph node metastases
at the time of the diagnosis. There were 511 (71.1 %) ER-
positive, 395 (54.9 %) PgR-positive and 163 (22.7 %)
HER2-positive cancers. After random allocation, 357
(49.7 %) patients were treated with docetaxel plus FEC,
362 (50.4 %) with vinorelbine plus FEC and 83 (50.9 %)
of the 163 patients with HER2-positive cancer received
trastuzumab. The median follow-up time after randomisa-
tion was 62 months, during which time period 112 patients
had distant cancer recurrence and 62 died.
Concordance between mRNA and IHC assays
Tumour ESR1, PGR and ERBB2mRNA content assessed by
RT-qPCR and the corresponding protein expressions
Table 1 Patient demographics, clinicopathological data and fre-
quencies of marker binary categories
N (%)
pT
N = 719
1 290 (40.33)
2 369 (51.32)
3 47 (6.54)
4 13 (1.81)
pN
N = 718
0 80 (11.14)
1 621 (86.49)
2 16 (2.23)
3 1 (0.14)
Histological type
N = 719
Ductal 575 (79.97)
Lobular 131 (18.22)
Papillary 2 (0.28)
Mucinous 2 (0.28)
Medullary 9 (1.25)
Histological grade
N = 694
I 102 (14.70)
II 287 (41.35)
III 305 (43.95)
Adjuvant chemotherapy
N = 719
Docetaxel 357 (49.65)
Vinorelbine 362 (50.35)
HER2-pos
N = 163
Trastuzumab 83 (50.92)
No Trastuzumab 80 (49.08)
Type of Surgery
N = 719
Total Mastectomy 430 (59.81)
Breast Conserving 289 (40.19)
440 Breast Cancer Res Treat (2016) 157:437–446
123
determined by IHC for ER and PgR and DNA amplification
status by CISH for HER2 showed good concordance,
whereas cancer MKI67 mRNA content and protein expres-
sion correlated only moderately well (Table 2). Many of the
discordant cases between IHC and the mRNA assay had a
high cancerMKI67 mRNA content, but despite this,\20 %
of cancer cell nuclei stained positively with IHC (Fig. 1).
Prognostic value of cancer MKI67 mRNA content
and Ki-67 expression
Patients with low breast tumour MKI67 mRNA content or
low (\20 %) Ki-67 expression had more favourable DDFS
and OS as compared to those with high MKI67 mRNA
content or Ki-67 expression. Each method produced
roughly similar hazard ratios for DDFS and OS (Fig. 2).
In a multivariate Cox regression analysis where the type
of chemotherapy (vinorelbine-FEC or docetaxel-FEC), the
axillary nodal status (pN0, pN1, pN2 or pN3), tumour size
(as a continuous variable), histological grade (as a con-
tinuous variable) and cancer MKI67 mRNA content (as a
continuous variable) were entered as covariables, low
tumour MKI67 mRNA content was independently associ-
ated with favourable DDFS (adjusted HR 0.51; 95 % CI,
0.29–0.90; P = 0.019) together with a negative axillary
nodal status (P\ 0.0001) and small cancer size
(P = 0.006). A low cancerMKI67 mRNA content was also
independently associated with favourable OS (adjusted HR
0.44; 95 % CI, 0.23-0.87; P = 0.018) in addition to the
axillary nodal status (P = 0.003) and tumour size
(P = 0.006). When Ki-67 protein expression was entered
into the same models in place of cancer mRNA content,
Ki-67 was not significantly associated with DDFS
(P = 0.266), but when OS was selected as the endpoint,
low cancer Ki-67 expression was associated with favour-
able survival (adjusted HR 0.43; 95 % CI, 0.24–0.77;
P = 0.005) together with the axillary nodal status
(P = 0.002) and small tumour size (P = 0.006).
Concordance of molecular subtyping with IHC
and RT-qPCR
The method of Ki-67 assessment had substantial impact on
making the distinction between luminal A and B cancers.
Of the 189 cancers that were classified as luminal A by
IHC/CISH, only 102 (54.0 %) were similarly classified,
when MKI67 mRNA expression was used in place of Ki-67
protein staining with the 87 discordant cases being classi-
fied as either luminal B (n = 75, 39.7 %) or HER2 positive
(n = 12, 6.4 %, Table 3). Of the 251 cancers that were
classified as luminal B by IHC/CISH, 180 (71.7 %) were
similarly classified using MKI67 mRNA expression, 48
(19.1 %) were classified as luminal A, 17 (6.8 %) as HER2
positive and 6 (2.4 %) as triple negative. Of the 156 and
294 tumours classified as luminal A and luminal B by RT-
Table 2 Agreement between
RT-qPCR-based and IHC-based
biomarker assessments
ESR1 PGR ERBB2 MKI67
Concordance 660/719 (91.8 %) 593/719 (82.5 %) 660/719 (91.8 %) 516/688 (75.0 %)
PPA 490/511 (95.9 %) 368/395 (93.2 %) 140/163 (85.9 %) 369/414 (89.1 %)
NPA 170/208 (81.7 %) 225/324(69.4 %) 520/556 (93.5 %) 147/274 (53.7 %)
Kappa statistic 0.80 (0.75–0.85) 0.64 (0.58–0.70) 0.77 (0.72–0.83) 0.45 (0.38–0.52)
P\ 0.0001 P\ 0.0001 P\ 0.0001 P\ 0.0001
PPA Positive percent agreement, NPA Negative percent agreement
Fig. 1 A scatterplot depicting the relation between tumour MKI67
mRNA content measured with RT-qPCR, and Ki-67 expression
determined by immunohistochemistry (IHC). Vertical axis, tumour
Ki-67 expression (IHC, %); horizontal axis, tumour relative MKI67
mRNA expression. The cut-off for positivity was 20 % in the Ki-67
protein assays (the horizontal line) and 34.8 in the MKI67 mRNA
(qPCR) assays (the vertical line). Sections A and D depict the
discordant cases, and sections B and C depict the concordant cases
Breast Cancer Res Treat (2016) 157:437–446 441
123
qPCR, respectively, 102 (65.4 %) and 180 (61.2 %) were
classified as luminal A or B also with IHC/CISH.
Influence of cancer MKI67 mRNA expression-based
and Ki-67 protein expression-based subtypes
on outcome
There was no significant difference in DDFS or OS
between patients treated with adjuvant docetaxel plus FEC
and those treated with vinorelbine and FEC in the subsets
with luminal A, HER2-positive or triple-negative breast
cancer when each subtype was defined either with IHC/
CISH or with RT-qPCR (DDFS and OS statistics for each
subtype according to chemotherapy agent shown in Sup-
plemental file 1E). Interestingly, when luminal B subtype
was defined by MKI67 mRNA expression, patients treated
with docetaxel plus FEC had significantly more favourable
DDFS and OS as compared with those treated with
vinorelbine plus FEC (for DDFS, HR 0.52, 95 % CI
0.29–0.94, P = 0.031; OS, HR 0.24, 95 % CI 0.09–0.65,
P = 0.005). In contrast no significant difference in DDFS
or OS was found, when the luminal B subtype was defined
Fig. 2 Influence of cancer MKI67 mRNA expression and Ki-67
protein expression on DDFS (panels a and c) and survival (panels
b and d). Results obtained by measuring MKI67 mRNA expression
are shown in panels a and b, and those obtained by assessing Ki-67
protein expression in panels c and d
Table 3 Concordance of breast
cancer subtypes when cancer
Ki-67 expression is assessed
with IHC and MKI67 mRNA
expression with RT-qPCR
RT-qPCR-based
Luminal A Luminal B HER2 pos TNBC Total
N (%) N (%) N (%) N (%) N (%)
IHC-based
Luminal A 102 65.4 75 25.5 12 6.8 0 0.0 189 26.3
Luminal B 48 30.8 180 61.2 17 9.7 6 6.5 251 34.9
HER2 pos 5 3.2 12 4.1 140 79.6 6 6.5 163 22.7
TNBC 1 0.6 27 9.2 7 4.0 81 87.1 116 16.1
Total 156 100.0 294 100.0 176 100.0 93 100.0 719 100.0
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with Ki-67 protein expression (P[ 0.10 for both analyses;
Fig. 3).
The type of adjuvant chemotherapy (tested docetaxel
plus FEC vs vinorelbine plus FEC) had an independent
influence on DDFS in the subset of patients who had
luminal B cancer defined by cancer MKI67 mRNA content
in a multivariable analysis (HR 0.44; 95 % CI 0.23–0.84,
P = 0.013), together with cancer histological grade (tested
as a continuous variable; HR 1.67, 95 % CI 1.03–2.72,
P = 0.039) and tumour size (tested as a continuous factor;
HR 1.02, 95 % CI 1.00–1.04, P = 0.026). Similarly, when
OS was used as the end point in place of DDFS and the
luminal B subtype was defined by cancer MKI67 mRNA
content, docetaxel-containing chemotherapy was indepen-
dently associated with favourable survival (HR 0.22; 95 %
CI 0.08–0.60, P = 0.003) together with histological grade
(HR 2.29, 95 % CI 1.15–4.57; P = 0.019), while tumour
size lost its significance. UnlikeMKI67 mRNA content, Ki-
67 protein expression did not have independent influence
on DDFS or OS in these models. When the luminal B
subtype was defined with tumour MKI67 mRNA content,
the interaction with the type of adjuvant chemotherapy
given was significant (P = 0.040) when OS was selected
as the end point, but not when DDFS was considered
(P = 0.352). No interaction with either OS or DDFS and
the type of adjuvant chemotherapy was present when the
luminal subtype was defined with Ki-67 protein expression
(P = 0.658 and 0.699, respectively).
Discussion
We approximated commonly used breast cancer biologi-
cal subtypes using RT-qPCR and compared the results
with the subtypes defined by IHC (and with CISH to
detect HER2 amplification) within the framework of a
large randomized clinical trial. The subtypes defined with
each method agreed moderately well with most discrep-
ancy occurring in the luminal B subtype. Both high
cancer Ki-67 protein expression and high MKI67 mRNA
content were associated with unfavourable DDFS and OS
in a univariable analysis with approximately similar
hazard ratios, but only tumour MKI67 mRNA content
remained significant in a multivariable model for DDFS
when both parameters were entered into the same model
after a stepwise selection process of the covariables such
as tumour size, nodal status, histological grade and the
type of treatment given.
Fig. 3 Distant metastasis-free survival (panels a and b) and overall
survival (panels c and d) of patients treated with adjuvant docetaxel
plus FEC and those treated with vinorelbine plus FEC in the subset of
patients with luminal B breast cancer. Panels a and c, the luminal B
subtype was defined with MKI67 mRNA expression; panels b and d,
the luminal B subtype was defined with Ki-67 protein expression
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A key difference between luminal A and luminal B
subtypes is a higher cell proliferation rate in the latter,
which is often assessed by estimating the proportion of
cancer cells that stain positively for Ki-67 after immuno-
histochemical staining. Interestingly, when the luminal B
type was defined using cancer MKI67 mRNA content in
place of Ki-67 expression assessed with immunohisto-
chemistry, patients with luminal B breast cancer were
found to benefit more from adjuvant docetaxel plus FEC
than from adjuvant vinorelbine plus FEC, which associa-
tion could not be detected when the luminal B breast
cancer subtype was defined by Ki-67 protein expression
with immunohistochemical staining.
Biological subtyping of breast cancer is the basis for
selection of systemic cancer treatment [1]. Of the four
biomarkers commonly used for this purpose, i.e. ER, PgR,
HER2 and Ki-67, the assays for Ki-67 have turned out the
most challenging ones to standardize and to make repro-
ducible. For example, in a study carried out in a few leading
pathology laboratories, there was substantial variability
between the laboratories in scoring of Ki-67 expression from
shared breast cancer tissue slides stained with IHC, and
attempts to reduce the interlaboratory variability were only
partially successful [4]. In the present study, IHC staining for
Ki-67was done locally inmany pathology laboratories using
the institutional staining protocols andwas assessed bymany
pathologists, whereas cancer MKI67 mRNA content was
determined centrally in one laboratory. To reduce the
potential variability in Ki-67 staining and scoring, we con-
sidered carrying out staining for Ki-67 also centrally, but due
to the difficulties to standardize Ki-67 immunostaining even
in leading laboratories and to establish a reference procedure
[4], we preferred to use the Ki-67 staining results reported
originally by the local laboratories fromwhole tumour tissue
sections as the comparator for the MKI67 mRNA assay.
Image analysis of Ki-67 from IHC stained slides is a
promising method to improve the reproducibility of Ki-67
scoring from immunostained slides, but, to our knowledge,
no standard parameter values for scoring of the nuclei as
either positive or negative are available. To estimate how
well the locally assessed Ki-67 assays done from whole
tumour tissue sections might correlate with a centrally done
Ki-67 assay, we analysed cancer Ki-67 expression from
TMAs (as whole tumour sections were not available) con-
taining tissue from 745 breast cancers using image analysis
[11]. The median cancer Ki-67 expression turned out to be
similar with image analysis and locally done IHC (19.7 and
20.0 %, respectively), and the two assays showed strong
correlation (P\ 0.0001, Spearman’s rho 0.633). These
observations suggest that centrally done image analysis of
Ki-67 might have resulted in similar conclusions had it been
selected as the comparator assay in place of the local Ki-67
IHC assays.
The subtypes defined with MKI67 mRNA were associ-
ated with survival outcomes that agree well with the results
obtained with IHC from other clinical trials [9, 10, 12–14].
Patients with the luminal A subtype had the best 5-year
DDFS, patients with HER2 positive and triple-negative
cancer had the least favourable outcomes, while patients
with luminal B cancer had an outcome intermediate of
these subtypes (see Supplement File 1E). These results are
well in agreement despite slight dissimilarities in the def-
inition of luminal B and HER2-positive subtypes between
the trials.
Taxane-containing adjuvant regimens are effective in
the treatment of early breast cancer but are associated with
side effects, and therefore, methods to optimize patient
selection for regimens that contain a taxane are needed.
The current finding that patients with luminal B cancer
have longer DDFS and OS when treated with docetaxel
plus FEC as compared with vinorelbine plus FEC is sup-
ported by observations made by Jacquemier et al. and Nitz
et al. who found that chemotherapy containing docetaxel
was associated with a significant reduction in the risk of
relapse in the subset of patients with luminal B breast
cancer in the PACS 01 trial [13] and WSG-AGO EC-Doc
trial [12], respectively. Both of these trials compared
docetaxel-containing regimens with standard anthracy-
cline-containing treatments. In the BCIRG 001 trial that
compared docetaxel, doxorubicin and cyclophosphamide
(TAC) versus fluorouracil, doxorubicin and cyclophos-
phamide (FAC) in the treatment of operable node-positive
breast cancer, only patients with ER-positive tumours with
either high Ki-67 expression or HER2 overexpression had a
statistically significant improvement in disease-free sur-
vival when treated with TAC [14]. However, unlike these
studies, we did not find a survival benefit from the doc-
etaxel-containing regimen in the subset of women with
HER2 positive cancer. In FinHer, half of the patients with
HER2-amplified cancer were randomly assigned to receive
adjuvant trastuzumab, which may have masked the
potential docetaxel benefit in this subtype and may have
reduced the statistical power to detect the association.
The PAM50 gene expression array has also been eval-
uated in predicting the potential benefit of adding a taxane
to anthracycline-based chemotherapy, but none of the
PAM50-derived subtypes including the luminal B subtype
were predictive for a taxane benefit in the GEICAM/9966
and the NCIC CTG MA.21 randomized phase III trials [15,
16]. Similarly the Endopredict gene expression assay did
not predict taxane benefit in the GEICAM/9966 study
population [17].
The limitations of the study include the retrospective
nature of the study, although we determined tumourMKI67
mRNA without knowledge of the clinical data and planned
the statistical analyses prospectively. We tested the
444 Breast Cancer Res Treat (2016) 157:437–446
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methods within the context of a relatively large randomized
trial but lacked a validation series, and some subgroup
analyses have limited power. However, the PCR method
used turned out to be reproducible across multiple testing
sites for all four biomarkers including MKI67 mRNA
(Laible et al., manuscript submitted for publication). The
details of the IHC methods used for assaying Ki-67 in the
local pathology laboratories were not captured during the
FinHer trial, as Ki-67 was not a protocol-mandated assay,
but most pathology laboratories in Finland assess Ki-67
from the tumour hot spot areas. The recommended cut-off
for ER and PgR positivity is now 1 % and no longer 10 %
as it was at the time when the FinHer trial accrued patients,
but the proportion of breast cancers where ER or PgR are
expressed in 1 % to 10 % of nuclei is small [18].
Conclusions
Measuring of cancer ESR1, PGR and ERBB2 mRNA cor-
related well with the results obtained with IHC and CISH
in clinical pathology laboratories. Tumour MKI67 mRNA
content quantitated with RT-qPCR is associated with
DDFS and OS of patients treated with modern adjuvant
regimens. The results suggest that assessment of tumour
MKI67 mRNA content may be valuable for selection of
patients for docetaxel-containing adjuvant therapy. Since
the immunohistochemical assay results for Ki-67 expres-
sion are challenging to transfer between laboratories, and
the assay for measuring cancer MKI67 mRNA content with
RT-qPCR might be less challenging to standardize than
IHC stainings, performing studies that evaluate interlabo-
ratory comparisons of cancer ESR1, PGR, ERBB2 and
MKI67 mRNA content using RT-qPCR are warranted.
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